The FDA just approved the first pill for late-stage pancreatic cancer. Here's what the headlines leave out.
The drug is RASONQUE (daraxonrasib). It blocks a protein called RAS, which drives more than 90% of pancreatic tumors. Scientists spent 40 years calling RAS undruggable. This is a real milestone. Nearly 53,000 Americans will die of pancreatic cancer this year.
You'll see "patients lived twice as long." That means about 13 months instead of about 7. That is real. It matters enormously to a family counting months. It's not a cure. Five-year survival for metastatic disease has been about 3%. A few patients in earlier trials have lived years. Doctors can't tell in advance who those patients will be.
Taking it is easier than chemo. One pill a day at home, no infusion chair. About 86% of people get a rash, and mouth sores and diarrhea are common. But severe side effects are less common than with chemo. Only 1% of patients quit because of side effects in the trials, compared with 11% on chemo.
The price is almost $40,000 a month. Nearly half a million dollars a year. The company expects insurance to cover most of it, and some people on private insurance will pay $0 out of pocket. But drugs priced like this raise premiums for everyone. And 70% of pancreatic cancer patients are 65 or older. That means Medicare. Medicare can't negotiate the price of this drug.
One thing to ask about: the FDA didn't require a genetic test to qualify. About 10% of pancreatic tumors don't carry a RAS mutation, and the benefit for those patients is unclear. Ask your oncologist about tumor sequencing.
Save this and share it with an oncologist, a caregiver, or anyone who's had this diagnosis in the family: Doctor explains what FDA'a approval of pancreatic cancer drug could mean for patients (CBS News)
Read & subscribe for free: celinegounder.com
#PancreaticCancer #DrugPricing #Oncology